6 days Ago By ABMN Staff
Geode Capital Management LLC lifted its stake in Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS – Free Report ) by 0.4% during the fourth quarter, HoldingsChannel reports.
The institutional investor owned 838,804 shares of the company’s stock after acquiring an additional 3,014 shares during the period. Geode Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $46,456,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock.
FMR LLC grew its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Tarsus Pharmaceuticals by 10.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company’s stock valued at $1,935,000 after purchasing an additional 5,709 shares during the period.
Wellington Management Group LLP boosted its position in shares of Tarsus Pharmaceuticals by 14.2% in the 3rd quarter. Wellington Management Group LLP now owns 145,347 shares of the company’s stock valued at $4,780,000 after purchasing an additional 18,019 shares during the period.
Barclays PLC grew its stake in Tarsus Pharmaceuticals by 345.9% during the 3rd quarter. Barclays PLC now owns 98,663 shares of the company’s stock worth $3,246,000 after buying an additional 76,538 shares during the last quarter.
Finally, Franklin Resources Inc. increased its position in Tarsus Pharmaceuticals by 9.3% during the third quarter.
Franklin Resources Inc. now owns 12,164 shares of the company’s stock worth $444,000 after buying an additional 1,033 shares during the period. 90.
01% of the stock is currently owned by institutional investors and hedge funds. Insider Activity In related news, insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction that occurred on Thursday, March 20th.
The shares were sold at an average price of $50.11, for a total transaction of $107,085.07.
Following the completion of the sale, the insider now owns 46,355 shares of the company’s stock, valued at approximately $2,322,849.05. This represents a 4.
41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, CEO Bobak R.
Azamian sold 7,131 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.
99. Following the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at approximately $3,273,628.80.
This trade represents a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last ninety days. Company insiders own 8.25% of the company’s stock.
Tarsus Pharmaceuticals Trading Up 4.9 % Tarsus Pharmaceuticals ( NASDAQ:TARS – Get Free Report ) last released its earnings results on Tuesday, February 25th. The company reported ($0.
60) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.08.
Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.
The firm had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million.
Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.
Analyst Ratings Changes A number of brokerages have recently issued reports on TARS. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.
00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Barclays lowered their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.
00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. HC Wainwright reissued a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th.
Guggenheim restated a “buy” rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th.
Finally, Jefferies Financial Group upped their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th.
One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $63.
67. Get Our Latest Stock Report on Tarsus Pharmaceuticals Tarsus Pharmaceuticals Company Profile ( Free Report ) Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Stories Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS – Free Report ).
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
